NR2F6 regulates Temozolomide resistance in glioma via the E2F2-PARP1 pathway.

ABSTRACT:

Background

Glioma is the most common primary malignant brain tumor in adults. Temozolomide (TMZ) represents a standard-of-care chemotherapeutic agent in glioblastoma (GBM). However, the development of drug resistance constitutes a significant hurdle in the treatment of malignant glioma. Elucidating the mechanisms of temozolomide (TMZ) resistance in glioma is of critical clinical importance for improving patient prognosis and developing novel therapeutic strategies.

Methods

We obtained RNA sequencing (RNA-seq) data of 648 glioma samples from The Cancer Genome Atlas (TCGA) and 325 samples from the Chinese Glioma Genome Atlas (CGGA) as study cohorts. Additionally, we validated the expression characteristics of the NR2F6 gene in our in-house cohort of glioma patients. Furthermor

SUBMITTER: Wang B 

PROVIDER: S-EPMC12542075 | biostudies-literature | 2025 Oct

REPOSITORIES: biostudies-literature